Home  »  Finance   »  Reata Pharmaceuticals Inc. (NASDAQ: RETA): Unlocki...

Reata Pharmaceuticals Inc. (NASDAQ: RETA): Unlocking Growth Opportunity

Reata Pharmaceuticals Inc. (NASDAQ:RETA) shares, rose in value on Friday, 05/13/22, with the stock price up by 8.49% to the previous day’s close as strong demand from buyers drove the stock to $24.54.

Actively observing the price movement in the last trading, the stock closed the session at $22.62, falling within a range of $23.15 and $25.25. The value of beta (5-year monthly) was 1.22. Referring to stock’s 52-week performance, its high was $153.41, and the low was $20.24. On the whole, RETA has fluctuated by -32.77% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.


With the market capitalization of Reata Pharmaceuticals Inc. currently standing at about $971.29 million, investors are eagerly awaiting this quarter’s results, scheduled for Feb 28, 2022 – Mar 04, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$2.31, which is expected to increase to -$2.01 for fiscal year -$8.09 and then to about -$8.6 by fiscal year 2022. Data indicates that the EPS growth is expected to be -10.10% in 2022, while the next year’s EPS growth is forecast to be -6.30%.

Analysts have estimated the company’s revenue for the quarter at $1.63 million, with a low estimate of $800k and a high estimate of $2.66 million. According to the average forecast, sales growth in current quarter could jump down -48.90%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $12.41 million, representing an increase of 37.60% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that RETA’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of RETA currently trading nearly -8.92% and -21.88% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 42.72, while the 7-day volatility ratio is showing 12.67% which for the 30-day chart, stands at 9.56%. Furthermore, Reata Pharmaceuticals Inc. (RETA)’s beta value is 1.25, and its average true range (ATR) is 2.55. The company’s stock has been forecasted to trade at an average price of $59.00 over the course of the next 52 weeks, with a low of $35.00 and a high of $93.00. Based on these price targets, the low is -42.62% off current price, whereas the price has to move -278.97% to reach the yearly target high. Additionally, analysts’ median price of $67.00 is likely to be welcomed by investors because it represents a decrease of -173.02% from the current levels.

A comparison of Reata Pharmaceuticals Inc. (RETA) with its peers suggests the former has fared considerably weaker in the market. RETA showed an intraday change of 8.49% in last session, and over the past year, it shrunk by -68.65%%. On the other hand, the price of Omeros Corporation (OMER) has risen 8.47% on the day. The stock, however, is off -82.42% from where it was a year ago. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 2.39%. Meanwhile, the Dow Jones Industrial Improved by 1.47%.

Data on historical trading for Reata Pharmaceuticals Inc. (NASDAQ:RETA) indicates that the trading volumes over the past 10 days have averaged 0.52 million and over the past 3 months, they’ve averaged 679.13K. According to company’s latest data on outstanding shares, there are 36.39 million shares outstanding.

Nearly 0.90% of Reata Pharmaceuticals Inc.’s shares belong to company insiders and institutional investors own 91.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.95 million shares as on Jan 30, 2022, resulting in a short ratio of 4.25. According to the data, the short interest in Reata Pharmaceuticals Inc. (RETA) stood at 8.10% of shares outstanding as of Jan 30, 2022; the number of short shares registered in Dec 30, 2021 reached 4.24 million. The stock has fallen by -6.94% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RETA stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts


New Outlook On Pfizer Inc.

Pfizer Inc. (NYSE:PFE) price on Thursday, May 26, rose 1.69% above its previous day’s close as an upside momentum from buyers pushed the stock’s value



Download Free eBook For


100% free. stop anytime no spam